Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.80 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180851 | 1.00 | DGAT1 (0.80) | DGAT1MCHR1PTPN1PTPN6PTPN11 | |
| SCHEMBL13664088 | 1.00 | DGAT1 (0.80) | DGAT1MCHR1PTPN1PTPN6PTPN11 | |
| SCHEMBL14643126 | 1.00 | DGAT1 (0.80) | DGAT1MCHR1PTPN1PTPN6PTPN11 | |
| SCHEMBL181095 | 1.00 | DGAT1 (0.80) | DGAT1MCHR1PTPN1PTPN6PTPN11 | |
| SCHEMBL180524 | 0.91 | DGAT1 (0.65) | DGAT1MCHR1PTPN1PTPN6PTPN11 | |
| SCHEMBL180647 | 0.90 | DGAT1 (0.69) | DGAT1MCHR1PTPN1PTPN6PTPN11 | |
| Pradigastat SCHEMBL1289309 | 0.89 | DGAT1 (1.00) | DGAT1 | |
| Pradigastat SCHEMBL29358725 | 0.89 | DGAT1 (1.00) | DGAT1 | |
| Pradigastat SCHEMBL16104874 | 0.89 | DGAT1 (1.00) | DGAT1 | |
| Pradigastat SCHEMBL180536 | 0.89 | DGAT1 (1.00) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-2418202-B1 | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885MCHR1 4196/4885PTPN1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.